Trial results for a feasibility study investigating intensive transcranial direct current stimulation (tDCS) for Major Depressive Disorder (MDD) were posted on 2025-07-28, reporting mean depressive symptom reductions of 21% and 31.5%.
Background
Major Depressive Disorder (MDD) is a common and debilitating mental health condition characterized by persistent sadness, loss of interest, and other symptoms that interfere with daily life. Current treatments include pharmacotherapy, psychotherapy, and neuromodulation techniques. Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique that delivers a low-level electrical current to specific brain areas. This study explored the safety and feasibility of an intensive tDCS treatment regimen for individuals with MDD, aiming to assess its potential as a therapeutic option.
Trial design
This completed study, designated as Phase NA, enrolled 30 participants aged 18-65 with a diagnosis of unipolar Major Depressive Disorder. It was designed as a prospective, open-label, single-arm study to determine the safety and feasibility of an intensive treatment of transcranial direct current stimulation (tDCS) for MDD. Participants received intensive tDCS over a 10-day treatment period and completed follow-up assessments at the end of treatment, and 1 and 4 weeks post-treatment.
Key results
The study reported key measurements related to the change in depressive symptoms as measured by the Patient Health Questionnaire (PHQ-9) for the active tDCS group:
- A mean percentage of change of 21% (Standard Deviation 31.9) was observed.
- Another mean percentage of change of 31.5% (Standard Deviation 34.8) was observed.
What this means
The posted results from this feasibility study provide initial insights into the potential of intensive tDCS for Major Depressive Disorder. The observed mean reductions in depressive symptoms, measured by the PHQ-9, suggest a positive direction of effect for this intensive treatment regimen. As a feasibility study, these findings primarily support the safety and viability of conducting such a treatment protocol. While promising, these results will need to be confirmed in larger, controlled trials to establish efficacy and clinical significance for patients with MDD.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT05194267, titled "Intensive tDCS for MDD: Feasibility Study", were posted on 2025-07-28 on clinicaltrials.gov.